IS7-15 A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ)
Scagliotti G, Kim D, Shaw A, Ou S, Riely G, Gettinger S, Besse B, Thomas M, Salgia R, Wilner K, Bartlett C, Polli A, Gandara D. IS7-15 A Large Retrospective Analysis of the Activity of Pemetrexed (PEM) in Patients (Patients) with ALK+ NSCLC Before Crizotinib (CRIZ). Annals Of Oncology 2012, 23: xi33. DOI: 10.1016/s0923-7534(20)32007-x.Peer-Reviewed Original ResearchObjective response rateMedian TTPPROFILE 1007Response rateLow objective response rateOngoing phase 3 trialsHigher objective response ratePhase 3 trialLarge retrospective analysisSingle-arm studySmall cohort studiesLarge phase 2High response rateAdenocarcinoma NSCLCBetter PFSCrossover patientsMedian PFSProgressive diseaseCohort studyNSCLC cohortRetrospective studyShorter TTPALK statusRetrospective analysisPemetrexed1267P A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment
Scagliotti G, Kim D, Shaw A, Ou S, Riely G, Gettinger S, Besse B, Wilner K, Tang Y, Bartlett C. 1267P A Large Retrospective Analysis of Pemetrexed (PEM) Activity in Patients (PTS) with Alk-Positive (Alk+) Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib (CRIZ) Treatment. Annals Of Oncology 2012, 23: ix415. DOI: 10.1016/s0923-7534(20)33862-x.Peer-Reviewed Original ResearchNon-small cell lung cancerHigher overall response rateOverall response rateMedian TTPRetrospective analysisALK-positive non-small cell lung cancerBest overall response rateYounger ageLower overall response rateSmall retrospective cohortLarge retrospective analysisSingle-arm studyCell lung cancerSmall cohort studiesLarge phase 2Similar demographic characteristicsBristol-Myers SquibbAdenocarcinoma histologyBetter PFSCrizotinib treatmentPemetrexed activityClinical characteristicsCohort studyFormer smokersRetrospective cohortA large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK -positive ( ALK +) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ).
Scagliotti G, Kim D, Shaw A, Ou S, Riely G, Gettinger S, Besse B, Thomas M, Salgia R, Wilner K, Bartlett C, Polli A, Gandara D. A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK -positive ( ALK +) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ). Journal Of Clinical Oncology 2012, 30: 7599-7599. DOI: 10.1200/jco.2012.30.15_suppl.7599.Peer-Reviewed Original ResearchNon-small cell lung cancerObjective response ratePROFILE 1007Median TTPAdenocarcinoma non-small cell lung cancerALK-positive non-small cell lung cancerResponse rateLow objective response rateOngoing phase 3 trialsHigher objective response ratePhase 3 trialSingle-arm studyLarge retrospective analysisCell lung cancerSmall cohort studiesLarge phase 2High response rateBetter PFSMedian PFSNSCLC cohortProgressive diseaseCohort studyRetrospective studyShorter TTPALK status